Recent patents on endocrine, metabolic & immune drug discovery最新文献_第9页

MAVS: a new weapon in the fight against viral infections. MAVS:对抗病毒感染的新武器。

Recent patents on endocrine, metabolic & immune drug discovery Pub Date : 2013-05-01 DOI: 10.2174/1872214811307020004

Jose A Boga, Maria de Oña, Santiago Melon, Marta E Alvarez-Arguelles, Ana Morilla, Ana Coto-Montes

引用次数: 6

The Wnt pathway: emerging anticancer strategies. Wnt通路:新兴的抗癌策略

Recent patents on endocrine, metabolic & immune drug discovery Pub Date : 2013-05-01 DOI: 10.2174/1872214811307020007

Aman Gupta, Anukriti Verma, Ashutosh K Mishra, Gulshan Wadhwa, Sanjeev K Sharma, Chakresh K Jain

{"title":"The Wnt pathway: emerging anticancer strategies.","authors":"Aman Gupta, Anukriti Verma, Ashutosh K Mishra, Gulshan Wadhwa, Sanjeev K Sharma, Chakresh K Jain","doi":"10.2174/1872214811307020007","DOIUrl":"https://doi.org/10.2174/1872214811307020007","url":null,"abstract":"The canonical Wnt cascade has emerged as a critical regulator of cancer cells. Activation of the Wnt signaling pathway has also been associated with stem cell, thus raising the possibility of its role in embryogenesis and in the proliferation of malignant cancer cells. Wnt pathway has been reported to be involved in normal physiological processes in adult animals and integrally associated with cancer cell growth and maintenance, thus has been harnessed to devise strategies for anticancer therapy. The presence or absence of some members in this pathway, such as β-catenin, Axin or APC, has been found to involve in different types of tumors in human beings. Dysregulation of the canonical Wnt/β-catenin signaling pathway, mostly by inactivating mutations of the APC tumor suppressor, or oncogenic mutations of β-catenin, has been implicated in colorectal tumorigenesis. Further, elevated levels of β-catenin protein, a hallmark of activated canonical Wnt pathway, have been significantly observed in common forms of human malignancies, indicating that activation of the Wnt pathway may play an important role in tumor development and hence could be a crucial consideration for drug development. The paper discusses the potential therapeutic and diagnostic strategies directing on Wnt pathways on the basis of recent patents and their analysis.","PeriodicalId":89474,"journal":{"name":"Recent patents on endocrine, metabolic & immune drug discovery","volume":"7 2","pages":"138-47"},"PeriodicalIF":0.0,"publicationDate":"2013-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31257248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 26

Editorial: Mitochondrion: an organelle more and more implication in new processes. 社论:线粒体:细胞器在新过程中越来越有意义。

Recent patents on endocrine, metabolic & immune drug discovery Pub Date : 2013-05-01 DOI: 10.2174/1872214811307020001

Ana Coto-Montes

引用次数: 3

Cognitive impairment and diabetes. 认知障碍和糖尿病。

Recent patents on endocrine, metabolic & immune drug discovery Pub Date : 2013-05-01 DOI: 10.2174/1872214811307020009

Sandip K Dash

{"title":"Cognitive impairment and diabetes.","authors":"Sandip K Dash","doi":"10.2174/1872214811307020009","DOIUrl":"https://doi.org/10.2174/1872214811307020009","url":null,"abstract":"The aim of this manuscript is to provide a brief review of the link between diabetes mellitus with cognitive impairment, the possible pathophysiology linking the two, and some possible therapeutic interventions for the treatment of this condition. The prevalence of diabetes increases with age, so also dementia increases in later life. As the population ages, type 2 diabetes and AD are increasing. Both diseases are chronic and are the leading causes of morbidity and mortality. Recent studies showed that older people with type 2 diabetes have a higher risk of cognitive decline. The precise mechanism linking the two remains to be found out. Several hypothetical mechanisms have been postulated. Type 2 diabetes is a risk factor for AD and vascular dementia. The association between diabetes and AD is particularly strong among carriers of the APOE ε4. Several studies have linked dementia to diabetes. Impaired fasting glucose and impaired glucose tolerance and insulin resistance have also been associated with poor cognitive performance and at risk of developing cognitive impairment. Studies have suggested that metabolic syndrome may be linked to vascular dementia, while contrasting findings showed the role of metabolic syndrome to AD. In this review, how diabetes and cognitive impairment and Alzheimer's disease are mutually linked, possible mechanism linking the two and some possible therapeutic interventions with some patents that seem to be good therapeutic targets in future are discussed.","PeriodicalId":89474,"journal":{"name":"Recent patents on endocrine, metabolic & immune drug discovery","volume":"7 2","pages":"155-65"},"PeriodicalIF":0.0,"publicationDate":"2013-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31305450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 30

Diabetic nephropathy: causes and managements. 糖尿病肾病:原因和管理。

Recent patents on endocrine, metabolic & immune drug discovery Pub Date : 2013-01-01

Yamini B Tripathi, Durgavati Yadav

引用次数: 0

tPA in the central nervous system: relations between tPA and cell surface LRPs. 中枢神经系统tPA: tPA与细胞表面lrp的关系。

Recent patents on endocrine, metabolic & immune drug discovery Pub Date : 2013-01-01

Saida Ortolano, Carlos Spuch

{"title":"tPA in the central nervous system: relations between tPA and cell surface LRPs.","authors":"Saida Ortolano, Carlos Spuch","doi":"","DOIUrl":"","url":null,"abstract":"A growing body of evidence has implicated the plasminogen activating system in various aspects of neurophysiology and pathophysiology. In ischemic stroke, blood-brain barrier (BBB) regulations, typically involving matrix metalloproteinases (MMPs), inhibitors tissue inhibitors of metalloproteinases (TIMPs) and the low density lipoprotein receptor- related protein/alpha 2-macroglobulin receptor (LRPs) as mediators became interesting since tissue plasminogen activator (tPA)-related BBB breakdown with risk of secondary hemorrhage was considered to involve these mediators too. The mechanism by which tPA implements its actions within the central nervous system (CNS) has been the topic of much controversy. Binding of plasminogen to surfaces is of crucial importance in regulating the function of this system. tPA can modulate permeability of the neurovascular unit in physiological conditions and pathological events exacerbating injury in ischemic stroke, vascular dementia, traumatic brain injury or neurotoxic events. The plasminogen activating enzyme system is widely appreciated for its role in fibrinolysis and thrombolysis and in other areas related to remodelling of the extracellular matrix. However, this enzyme system also has a major impact in the central nervous system under pathological circumstances. The aim of this review is to revise the last patents and news to understand the mechanism by which t-PA modulates BBB permeability.","PeriodicalId":89474,"journal":{"name":"Recent patents on endocrine, metabolic & immune drug discovery","volume":"7 1","pages":"65-76"},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31115073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Anti-allergic potential of herbs and herbal natural products - activities and patents. 草药和天然草药产品的抗过敏潜力-活性和专利。

Recent patents on endocrine, metabolic & immune drug discovery Pub Date : 2013-01-01

Betania B Cota, Caryne M Bertollo, Djalma M de Oliveira

{"title":"Anti-allergic potential of herbs and herbal natural products - activities and patents.","authors":"Betania B Cota, Caryne M Bertollo, Djalma M de Oliveira","doi":"","DOIUrl":"","url":null,"abstract":"The increase of allergic diseases has accompanied the global population growth and the major challenge is to reduce morbidity. The currently available treatments present limitations regarding efficacy and safety. Hence, patients with chronic allergic conditions seek alternatives to achieve better control of symptoms. Many natural products have been identified as potential anti-allergic agents. In addition, plant formulations have demonstrated, in general, to be safe in clinical trials and demonstrate additional effects along with Western medicines such as synergism and modulation of the immune system. It is known that plants represent a source of new therapeutic agents and some of them have shown mechanisms of action similar to synthetic agents. However, in general, herbs and their combination are patented mainly by Asian countries to be used in food and drinks or cosmetics and dietary supplements and the anti-allergic mechanisms of action are not yet fully elucidated. In this review, we highlight relevant patent and studies with cultivated plants, plant formulations, and secondary metabolites that have been evaluated with respect to its anti-allergic potential.","PeriodicalId":89474,"journal":{"name":"Recent patents on endocrine, metabolic & immune drug discovery","volume":"7 1","pages":"26-56"},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30878979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Metabolic syndrome, its pathophysiology and the role of melatonin. 代谢综合征的病理生理及褪黑素的作用。

Recent patents on endocrine, metabolic & immune drug discovery Pub Date : 2013-01-01

Venkataramanujam Srinivasan, Yoshiji Ohta, Javier Espino, Jose A Pariente, Ana B Rodriguez, Mahaneem Mohamed, Rahimah Zakaria

{"title":"Metabolic syndrome, its pathophysiology and the role of melatonin.","authors":"Venkataramanujam Srinivasan, Yoshiji Ohta, Javier Espino, Jose A Pariente, Ana B Rodriguez, Mahaneem Mohamed, Rahimah Zakaria","doi":"","DOIUrl":"","url":null,"abstract":"Metabolic syndrome (MetS) is characterised by symptoms of obesity, insulin resistance, hypertension, dyslipidemia and diabetes mellitus. The pathophysiological mechanisms involved in MetS are complex and involved dysregulation of many biochemical and physiological regulatory mechanisms of the body. Elevated levels of low density lipoproteins like VLDL, and LDL with reduction of HDL seen in patients with MetS contribute to atherogenic dyslipedemia. Melatonin has been suggested to be effective in improving MetS through its anti-hyperlipidemic action. Melatonin reduced both adiposity, and body weight in experimental animal studies and also attenuated weight gain and obesityinduced metabolic alterations and this effect of melatonin is attributed to its anti-oxidative effects. Melatonin administration has been shown to inhibit insulin release by acting through both MT1 and MT2 melatonin receptors present in pancreatic β-cells. Melatonin also increased insulin sensitivity and glucose tolerance in animals fed with either high fat or high sucrose diet. Melatonin exerts most of its beneficial actions by acting through MT1 and MT2 melatonin receptors present in various tissues of the body and some of the metabolic actions of melatonin have been blocked by melatonin antagonist like luzindole. Ramelteon, the newly available melatonin agonist will also have more promising role in the control of MetS. The numbers of patents are available with regard to treatment of MetS. Drug related to antidepressant fluoxetine is used for treatment of MetS (US Patent No. 2008001400450). Anti-oxidants like S-adenosyl-methionine, Vitamin E, and Vitamin C have been found beneficial in treating MetS (US Patent No. 8063024). Melatonin being a powerful Antioxidant will have a promising role in treating patients with metabolic syndrome.","PeriodicalId":89474,"journal":{"name":"Recent patents on endocrine, metabolic & immune drug discovery","volume":"7 1","pages":"11-25"},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30879310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cancer therapy based on a mechanism of action for controlling the immune system and the resulting patent portfolio. 基于控制免疫系统的作用机制和由此产生的专利组合的癌症治疗。

Recent patents on endocrine, metabolic & immune drug discovery Pub Date : 2013-01-01

Visala C Goswitz, Z Peter Sawicki

引用次数: 0

Affective disorder and hyperandrogenism. 情感性障碍和高雄激素症。

Recent patents on endocrine, metabolic & immune drug discovery Pub Date : 2013-01-01

Celen Zerouni, Elaine Kummerow, Mariflor Martinez, Ana Diaz, Uribe Ezequiel, Richard Wix-Ramos

引用次数: 0